New Clinical Trial Data - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

New Clinical Trial Data

DAWN, GILD, IMGN, LEGN, NASDAQ, ONCY

#Cancer #New Clinical Trial Data #Trending News #Upcoming Presentation

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

May 26, 2023
10:53

EST

FN Media Group Presents USA News Group News Commentary VANCOUVER, B.C., May 26, 2023 /PRNewswire/ — USA News Group – The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May.

No Comments

NASDAQ, YMAB

#Cancer #New Clinical Trial Data

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

May 26, 2023
09:00

EST

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring interim clinical data on naxitamab, a

No Comments

IMMP, NASDAQ

#Event #New Clinical Trial Data #Trending News

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

May 26, 2023
08:00

EST

Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet

No Comments

OTC, RHHBY

#Cancer #New Clinical Trial Data #Upcoming Presentation

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023

May 26, 2023
01:00

EST

Basel, 26 May 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for

No Comments

AADI, NASDAQ

#Cancer #Distribution Agreement #Event #New Clinical Trial Data #Trending News

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023
17:30

EST

LOS ANGELES, May 25, 2023 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago,

No Comments

MTD, NYSE

#New Clinical Trial Data #Upcoming Presentation

Mettler-Toledo International Inc. Announces Webcast of Presentation at the Jefferies Healthcare Conference

May 25, 2023
17:15

EST

Columbus, OH, May 25, 2023 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m Eastern Time. To hear a live webcast of the presentation, visit the investor relations page on the Company’s

No Comments

NASDAQ, SWTX

#Cancer #Event #New Clinical Trial Data #Phase 3 #Trending News

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

May 25, 2023
17:05

EST

– Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools – – Substantial Reductions in MRI-Assessed Tumor Volume and T2 Hyperintensity Observed with Nirogacestat Compared to Placebo – STAMFORD, Conn., May 25, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX),

No Comments

BOLT, NASDAQ

#Cancer #Event #New Clinical Trial Data #Phase 1

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

May 25, 2023
17:05

EST

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab 20 mg/kg dosed every other week (q2w) was selected as the RP2D BDC-1001 advancing to a focused Phase 2

No Comments

NASDAQ, TERN

#Distribution Agreement #Event #Hepatitis #New Clinical Trial Data #Trending News

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

May 25, 2023
17:05

EST

– Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023 – China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or

No Comments

NASDAQ, RLAY

#Featured #New Clinical Trial Data #Trending News

Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008

May 25, 2023
17:01

EST

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of

No Comments

< Page1 Page2 Page3 … Page225 >

Trending News

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

05/26/2023

SILVERCORP DECLARES SEMI-ANNUAL DIVIDEND OF US$0.0125 PER SHARE

05/26/2023

Halo Collective Provides Update on Status of Financial Statements

05/26/2023

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

05/26/2023

US Investors May Now Have Trading Access for Genius Group Shares on Upstream through US Broker Dealer

05/26/2023

Most read news

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn’s Disease

05/25/2023

Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.

05/24/2023

Avante Announces Private Placement Closing

05/24/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account